A Phase 3 interventional study of Placebo and MT-7117 Low Dose in EPP and XLP, sponsored by Tanabe Pharma America, Inc.. Completed at 31 sites in 10 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-30.
Sponsored by Tanabe Pharma America, Inc. (part of Tanabe Pharma Corporation) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, itching, or stinging) associated with sunlight exposure in adults and adolescents with EPP or XLP aged 12-75.
Tanabe Pharma America, Inc. is the lead sponsor of 13 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additional screening criteria check may apply for qualification.
Inclusion Criteria:
Exclusion Criteria:
Presence of squamous cell carcinoma, basal cell carcinoma, or other malignant skin lesions.
Any suspicious lesions or nevi will be evaluated. If the suspicious lesion or nevi cannot be resolved through or excision, the subject will be excluded from the study.
Chronic treatment with any scheduled analgesic agents including, but not limited to, opioids and opioid derivatives such as morphine, hydrocodone, oxycodone, fentanyl, or their combination with other unscheduled analgesics or non-steroidal anti-inflammatory drug (Percocet and Vicodin-like prescription drugs) within 4 weeks before Randomization (Visit 2).
Acute use of scheduled narcotics greater than 3 months prior to randomization, OTCs, such as NSAIDs or aspirin for analgesia, or prior temporary use of scheduled agents within 3 months of screening are not excluded.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral tablet of placebo once a day.
Drug: Placebo
Oral tablet of MT-7117 Low Dose once a day.
Drug: MT-7117 Low Dose
Oral tablet of MT-7117 High Dose once a day.
Drug: MT-7117 High Dose
Placebo
MT-7117 Low Dose
Also known as: Dersimelagon
MT-7117 High Dose
Also known as: Dersimelagon
Change From Baseline in Average Daily Sunlight Exposure Time (Minutes) to First Prodromal Symptom (Burning, Tingling, Itching, or Stinging) Associated With Sunlight Exposure Between 1 Hour Post Sunrise and 1 Hour Pre-sunset at Week 26 (Visit 7)
Time frame: From 1 hour post-sunrise to 1 hour pre-sunset at Week 26 (Visit 7)
Patient Global Impression of Change (PGIC) at Week 26
PGIC: Scale from 1 to 7, where 7 is worse.
Time frame: Week 26
Total Number of Sunlight-induced Pain Events Defined as Prodrome Symptoms (Burning, Tingling, Itching, or Stinging) With Pain Rating of 1-10 on the Likert Scale During the 26-week Double-blind Treatment Period.
The Likert scale used ranges from 0 to 10, where 0 indicates the lowest pain rating and 10 indicates the highest pain rating. Likewise, 0 indicates to best outcome and 10 indicates the worst outcome. The sum of the number of pain events with pain rating of 1 to 10 for the day is used as the number of sunlight-induced pain events in the day. The sum of the number of the pain events with pain rating of 1 to 10 in each day during the 26-week Double-blind Treatment Period is calculated as this endpoint.
Time frame: During the 26-week double-blind treatment period
Change From Baseline for Total Score in the Domain of Pain Intensity in the PROMIS-57 at Week 26
Pain intensity: 0 to 10, where 10 is worst pain imaginable.
Time frame: Baseline (Week 0) and Week 26
The Percentage of Subjects Who Are Responders
The percentage of subjects who are responders based on average daily sunlight exposure time to first prodromal symptom associated with sunlight exposure between 1 hour post-sunrise and 1 hour presunset defined by within-subject meaningful change of 66 minutes increase from baseline to Week 26
Time frame: Week 26
Change From Baseline for Total Score in the Domain of Physical Function in the PROMIS-57 at Week 26
Physical function: 1-5, where 5 is without any difficulty.
Time frame: Baseline (Week 0) and Week 26
| Milestone | Placebo | MT-7117 Low Dose | MT-7117 High Dose | Placebo -> MT-7117 Low Dose | Placebo -> MT-7117 High Dose |
|---|---|---|---|---|---|
| Started | 61 | 63 | 60 | 0 | 0 |
| Completed | 57 | 60 | 58 | 0 | 0 |
| Not completed | 4 | 3 | 2 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 2 | 2 | 0 | 0 |
| Milestone | Placebo | MT-7117 Low Dose | MT-7117 High Dose | Placebo -> MT-7117 Low Dose | Placebo -> MT-7117 High Dose |
|---|---|---|---|---|---|
| Started | 0 | 56 | 55 | 28 | 28 |
| Completed | 0 | 55 | 52 | 27 | 28 |
| Not completed | 0 | 1 | 3 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 2 | 0 | 0 |
| minute | DBT ITT1 Placebo | DBT ITT1 MT- 7117 Low Dose | DBT ITT1 MT- 7117 High Dose |
|---|---|---|---|
| Change From Baseline in Average Daily Sunlight Exposure Time (Minutes) to First Prodromal Symptom (Burning, Tingling, Itching, or Stinging) Associated With Sunlight Exposure Between 1 Hour Post Sunrise and 1 Hour Pre-sunset at Week 26 (Visit 7) | 20.59 ± 10.29 | 30.39 ± 10.04 | 43.29 ± 10.13 |
PGIC: Scale from 1 to 7, where 7 is worse.
| point | DBT ITT1 Placebo | DBT ITT1 MT- 7117 Low Dose | DBT ITT1 MT- 7117 High Dose |
|---|---|---|---|
| Patient Global Impression of Change (PGIC) at Week 26 | 3.25 ± 1.14 | 2.41 ± 0.14 | 1.82 ± 0.14 |
The Likert scale used ranges from 0 to 10, where 0 indicates the lowest pain rating and 10 indicates the highest pain rating. Likewise, 0 indicates to best outcome and 10 indicates the worst outcome. The sum of the number of pain events with pain rating of 1 to 10 for the day is used as the number of sunlight-induced pain events in the day. The sum of the number of the pain events with pain rating of 1 to 10 in each day during the 26-week Double-blind Treatment Period is calculated as this endpoint.
| events | DBT ITT1 Placebo | DBT ITT1 MT- 7117 Low Dose | DBT ITT1 MT- 7117 High Dose |
|---|---|---|---|
| Total Number of Sunlight-induced Pain Events Defined as Prodrome Symptoms (Burning, Tingling, Itching, or Stinging) With Pain Rating of 1-10 on the Likert Scale During the 26-week Double-blind Treatment Period. | 23.9 ± 30.93 | 15.87 ± 22.05 | 13.78 ± 18.7 |
Pain intensity: 0 to 10, where 10 is worst pain imaginable.
| total score | DBT ITT1 Placebo | DBT ITT1 MT- 7117 Low Dose | DBT ITT1 MT- 7117 High Dose |
|---|---|---|---|
| Change From Baseline for Total Score in the Domain of Pain Intensity in the PROMIS-57 at Week 26 | -1.42 ± 0.18 | -1.56 ± 0.16 | -1.65 ± 0.17 |
The percentage of subjects who are responders based on average daily sunlight exposure time to first prodromal symptom associated with sunlight exposure between 1 hour post-sunrise and 1 hour presunset defined by within-subject meaningful change of 66 minutes increase from baseline to Week 26
| percentage of participants | DBT ITT1 Placebo | DBT ITT1 MT- 7117 Low Dose | DBT ITT1 MT- 7117 High Dose |
|---|---|---|---|
| The Percentage of Subjects Who Are Responders | 12 | 11 | 16 |
Physical function: 1-5, where 5 is without any difficulty.
| total score | DBT ITT1 Placebo | DBT ITT1 MT- 7117 Low Dose | DBT ITT1 MT- 7117 High Dose |
|---|---|---|---|
| Change From Baseline for Total Score in the Domain of Physical Function in the PROMIS-57 at Week 26 | 0.67 ± 0.36 | 1.54 ± 0.32 | 1.22 ± 0.33 |
Collected over through study completion, an average of 58 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DBT: Placebo | 0/61 (0%) | 0/61 (0%) | 30/61 (49.2%) |
| DBT: MT-7117 Low Dose | 0/63 (0%) | 2/63 (3.2%) | 35/63 (55.6%) |
| DBT: MT-7117 High Dose | 1/60 (1.7%) | 2/60 (3.3%) | 40/60 (66.7%) |
| DBE: MT-7117 Low Dose Switched From Placebo | 0/28 (0%) | 2/28 (7.1%) | 19/28 (67.9%) |
| DBE: MT-7117 High Dose Switched From Placebo | 0/28 (0%) | 1/28 (3.6%) | 18/28 (64.3%) |
| DBE: MT-7117 Low Dose | 0/56 (0%) | 1/56 (1.8%) | 24/56 (42.9%) |
| DBE: MT-7117 High Dose | 0/54 (0%) | 2/54 (3.7%) | 21/54 (38.9%) |
| Event | DBT: Placebo | DBT: MT-7117 Low Dose | DBT: MT-7117 High Dose | DBE: MT-7117 Low Dose Switched From Placebo | DBE: MT-7117 High Dose Switched From Placebo | DBE: MT-7117 Low Dose | DBE: MT-7117 High Dose |
|---|---|---|---|---|---|---|---|
| Hepatic enzyme increasedInvestigations | 0/61 | 0/63 | 0/60 | 2/28 | 0/28 | 0/56 | 0/54 |
| Porphyria non-acuteCongenital, familial and genetic disorders | 0/61 | 0/63 | 0/60 | 0/28 | 1/28 | 0/56 | 0/54 |
| OesophagitisGastrointestinal disorders | 0/61 | 0/63 | 0/60 | 0/28 | 0/28 | 0/56 | 1/54 |
| Fibula fractureInjury, poisoning and procedural complications | 0/61 | 0/63 | 0/60 | 0/28 | 0/28 | 0/56 | 1/54 |
| PericarditisCardiac disorders | 0/61 | 0/63 | 0/60 | 0/28 | 0/28 | 1/56 | 0/54 |
| CholestasisHepatobiliary disorders | 0/61 | 0/63 | 1/60 | 0/28 | 0/28 | 0/56 | 0/54 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/61 | 0/63 | 1/60 | 0/28 | 0/28 | 0/56 | 0/54 |
| MyocarditisCardiac disorders | 0/61 | 1/63 | 0/60 | 0/28 | 0/28 | 0/56 | 0/54 |
| Meningitis viralInfections and infestations | 0/61 | 1/63 | 0/60 | 0/28 | 0/28 | 0/56 | 0/54 |
| Event | DBT: Placebo | DBT: MT-7117 Low Dose | DBT: MT-7117 High Dose | DBE: MT-7117 Low Dose Switched From Placebo | DBE: MT-7117 High Dose Switched From Placebo | DBE: MT-7117 Low Dose | DBE: MT-7117 High Dose |
|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 2/61 | 5/63 | 1/60 | 7/28 | 8/28 | 11/56 | 10/54 |
| NauseaGastrointestinal disorders | 4/61 | 4/63 | 17/60 | 1/28 | 5/28 | 1/56 | 2/54 |
| HeadacheNervous system disorders | 3/61 | 8/63 | 9/60 | 2/28 | 3/28 | 2/56 | 2/54 |
| Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/61 | 6/63 | 8/60 | 4/28 | 3/28 | 3/56 | 2/54 |
| DiarrhoeaGastrointestinal disorders | 1/61 | 5/63 | 8/60 | 0/28 | 1/28 | 0/56 | 1/54 |
| Skin hyperpigmentationSkin and subcutaneous tissue disorders | 1/61 | 3/63 | 8/60 | 2/28 | 3/28 | 0/56 | 0/54 |
| Aspartate aminotransferase increasedInvestigations | 1/61 | 4/63 | 0/60 | 3/28 | 1/28 | 1/56 | 1/54 |
| Blood creatine phosphokinase increasedInvestigations | 0/61 | 1/63 | 1/60 | 3/28 | 0/28 | 1/56 | 0/54 |
| Vitamin D deficiencyMetabolism and nutrition disorders | 0/61 | 1/63 | 0/60 | 3/28 | 1/28 | 3/56 | 2/54 |
| ParaesthesiaNervous system disorders | 0/61 | 1/63 | 0/60 | 3/28 | 1/28 | 0/56 | 0/54 |
| Age, Categorical(Participants) | Placebo | MT-7117 Low Dose | MT-7117 High Dose | Total |
|---|---|---|---|---|
| <=18 years | 12 | 13 | 12 | 37 |
| Between 18 and 65 years | 47 | 45 | 46 | 138 |
| >=65 years | 2 | 5 | 2 | 9 |
| Sex: Female, Male(Participants) | Placebo | MT-7117 Low Dose | MT-7117 High Dose | Total |
|---|---|---|---|---|
| Female | 30 | 30 | 33 | 93 |
| Male | 31 | 33 | 27 | 91 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | MT-7117 Low Dose | MT-7117 High Dose | Total |
|---|---|---|---|---|
| Hispanic or Latino | 7 | 7 | 2 | 16 |
| Not Hispanic or Latino | 53 | 52 | 58 | 163 |
| Unknown or Not Reported | 1 | 4 | 0 | 5 |
| Race (NIH/OMB)(Participants) | Placebo | MT-7117 Low Dose | MT-7117 High Dose | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 9 | 1 | 2 | 12 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 52 | 60 | 55 | 167 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 2 | 2 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jun 2020 to primary completion in Dec 2021, 18 months.
Results were first posted in Mar 2025, 3 years 3 months after primary completion. A results delay was requested in Dec 2022.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dersimelagon